391 related articles for article (PubMed ID: 15623598)
1. Matrix metalloproteinase/tissue inhibitors of matrix metalloproteinase phenotype identifies poor prognosis colorectal cancers.
Curran S; Dundas SR; Buxton J; Leeman MF; Ramsay R; Murray GI
Clin Cancer Res; 2004 Dec; 10(24):8229-34. PubMed ID: 15623598
[TBL] [Abstract][Full Text] [Related]
2. Prognostic values of matrix metalloproteinase family expression in human colorectal carcinoma.
Asano T; Tada M; Cheng S; Takemoto N; Kuramae T; Abe M; Takahashi O; Miyamoto M; Hamada J; Moriuchi T; Kondo S
J Surg Res; 2008 May; 146(1):32-42. PubMed ID: 17543340
[TBL] [Abstract][Full Text] [Related]
3. Profiling markers of prognosis in colorectal cancer.
Lyall MS; Dundas SR; Curran S; Murray GI
Clin Cancer Res; 2006 Feb; 12(4):1184-91. PubMed ID: 16489072
[TBL] [Abstract][Full Text] [Related]
4. Limited value of preoperative serum analyses of matrix metalloproteinases (MMP-2, MMP-9) and tissue inhibitors of matrix metalloproteinases (TIMP-1, TIMP-2) in colorectal cancer.
Oberg A; Höyhtyä M; Tavelin B; Stenling R; Lindmark G
Anticancer Res; 2000; 20(2B):1085-91. PubMed ID: 10810401
[TBL] [Abstract][Full Text] [Related]
5. Expression of matrix metalloproteinases and their inhibitors in medulloblastomas and their prognostic relevance.
Ozen O; Krebs B; Hemmerlein B; Pekrun A; Kretzschmar H; Herms J
Clin Cancer Res; 2004 Jul; 10(14):4746-53. PubMed ID: 15269148
[TBL] [Abstract][Full Text] [Related]
6. The matrix metalloproteinase/tissue inhibitor of matrix metalloproteinase profile in colorectal polyp cancers.
Jeffery N; McLean MH; El-Omar EM; Murray GI
Histopathology; 2009 Jun; 54(7):820-8. PubMed ID: 19635101
[TBL] [Abstract][Full Text] [Related]
7. Correlation of matrix metalloproteinases and tissue inhibitors of matrix metalloproteinase expression in ileal carcinoids, lymph nodes and liver metastasis with prognosis and survival.
Voland P; Besig S; Rad R; Braun T; Baur DM; Perren A; Langer R; Höfler H; Prinz C
Neuroendocrinology; 2009; 89(1):66-78. PubMed ID: 18708724
[TBL] [Abstract][Full Text] [Related]
8. Matrix metalloproteinases, their tissue inhibitors and colorectal cancer staging.
Baker EA; Bergin FG; Leaper DJ
Br J Surg; 2000 Sep; 87(9):1215-21. PubMed ID: 10971431
[TBL] [Abstract][Full Text] [Related]
9. Clinicopathological assessment and quantitative estimation of the matrix metalloproteinases MMP-2 and MMP-7 and the inhibitors TIMP-1 and TIMP-2 in colorectal carcinoma tissue samples.
Pesta M; Topolcan O; Holubec L; Rupert K; Cerna M; Holubec LS; Treska V; Finek J; Cerny R
Anticancer Res; 2007; 27(4A):1863-7. PubMed ID: 17649785
[TBL] [Abstract][Full Text] [Related]
10. [Expression of matrix metalloproteinases and tissue inhibitor of metalloproteinases in colorectal neoplasm].
Wan Y; Wei Q; Pan Y; Liu Y
Zhonghua Wai Ke Za Zhi; 2000 Jul; 38(7):510-3. PubMed ID: 11832095
[TBL] [Abstract][Full Text] [Related]
11. Expression and prognostic significance of matrix metalloproteinases and their tissue inhibitors in primary neuroendocrine carcinoma of the skin.
Massi D; Franchi A; Ketabchi S; Paglierani M; Pimpinelli N; Santucci M
Hum Pathol; 2003 Jan; 34(1):80-8. PubMed ID: 12605370
[TBL] [Abstract][Full Text] [Related]
12. Tissue inhibitor of metalloproteinase 1 is an independent predictor of prognosis in patients with nonsmall cell lung carcinoma who undergo resection with curative intent.
Gouyer V; Conti M; Devos P; Zerimech F; Copin MC; Créme E; Wurtz A; Porte H; Huet G
Cancer; 2005 Apr; 103(8):1676-84. PubMed ID: 15754326
[TBL] [Abstract][Full Text] [Related]
13. Gelatinase B expression as a prognostic factor in patients with stage II/III rectal carcinoma treated by postoperative adjuvant therapy.
Unsal D; Akyurek N; Uner A; Erpolat OP; Han U; Akmansu M; Mentes BB; Dursun A
Am J Clin Oncol; 2008 Feb; 31(1):55-63. PubMed ID: 18376229
[TBL] [Abstract][Full Text] [Related]
14. Expression and distribution of MMPs and TIMPs in human uveal melanoma.
Lai K; Conway RM; Crouch R; Jager MJ; Madigan MC
Exp Eye Res; 2008 Jun; 86(6):936-41. PubMed ID: 18423620
[TBL] [Abstract][Full Text] [Related]
15. Quantitative estimation of matrix metalloproteinases 2 and 7 (MMP-2, MMP-7) and tissue inhibitors of matrix metalloproteinases 1 and 2 (TIMP-1, TIMP-2) in colorectal carcinoma tissue samples.
Pesta M; Holubec L; Topolcan O; Cerna M; Rupert K; Holubec LS; Treska V; Kormunda S; Elgrova L; Finek J; Cerny R
Anticancer Res; 2005; 25(5):3387-91. PubMed ID: 16101153
[TBL] [Abstract][Full Text] [Related]
16. Tissue MMP-2 and MMP-9 [corrected] are better prognostic factors than serum MMP-2/TIMP-2--complex or TIMP-1 [corrected] in stage [corrected] I-III lung carcinoma.
Hoikkala S; Pääkkö P; Soini Y; Mäkitaro R; Kinnula V; Turpeenniemi-Hujanen T
Cancer Lett; 2006 May; 236(1):125-32. PubMed ID: 15982804
[TBL] [Abstract][Full Text] [Related]
17. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
Naka T; Kuester D; Boltze C; Schulz TO; Samii A; Herold C; Ostertag H; Roessner A
Hum Pathol; 2008 Feb; 39(2):217-23. PubMed ID: 17949787
[TBL] [Abstract][Full Text] [Related]
18. Predictive value of lymph node and tumor matrix metalloproteinase expression in the analysis of metastatic periampullary tumors.
McKenna GJ; Meneghetti A; Chen YL; Mui AL; Ong C; Scudamore CH; McMaster WR; Owen DA; Chung SW
J Surg Oncol; 2005 Jun; 90(4):239-46. PubMed ID: 15906368
[TBL] [Abstract][Full Text] [Related]
19. Increased expression of matrix metalloproteinases 2 and 9 and tissue inhibitors of metalloproteinases 1 and 2 correlate with poor prognostic variables in renal cell carcinoma.
Kallakury BV; Karikehalli S; Haholu A; Sheehan CE; Azumi N; Ross JS
Clin Cancer Res; 2001 Oct; 7(10):3113-9. PubMed ID: 11595703
[TBL] [Abstract][Full Text] [Related]
20. Expression of matrix metalloproteinases and tissue inhibitors of metalloproteinase in uterine endometrial carcinoma and a correlation between expression of matrix metalloproteinase-7 and prognosis.
Misugi F; Sumi T; Okamoto E; Nobeyama H; Hattori K; Yoshida H; Matsumoto Y; Yasui T; Honda K; Ishiko O
Int J Mol Med; 2005 Oct; 16(4):541-6. PubMed ID: 16142384
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
